Home/Manzanita Pharmaceuticals/Stephen B. Kahl

SB

Stephen B. Kahl

Chief Scientific Officer, VP & Principal Scientist

Manzanita Pharmaceuticals

Therapeutic Areas

Oncology Neurology Pain

Manzanita Pharmaceuticals Pipeline

Drug	Indication	Phase
NerveLight (800-rhNGF)	Nerve imaging for prostatectomy (prostate cancer surgery)	Pre-clinical

Leadership Team at Manzanita Pharmaceuticals

Constance McKee

President & CEO

View full Manzanita Pharmaceuticals profile